降钙素原、C反应蛋白与中性粒细胞/淋巴细胞比值对急诊科COPD急性加重患者无创机械通气失败的预测比较
该前瞻性队列研究在三级中心急诊科纳入2023年3月至2024年12月连续就诊、符合无创通气指征的COPD急性加重患者151例,评估C反应蛋白、降钙素原和中性粒细胞/淋巴细胞比值对无创通气失败的预测能力。151例中73例(48.3%)发生无创通气失败,相关死亡率为30.1%。ROC分析显示NLR的AUC为0.804(95%CI 0.734-0.875),优于CRP的0.680(95%CI 0.594-0.765)和降钙素原的0.682(95%CI 0.596-0.767);NLR预测无创通气失败的最佳界值为5.8,敏感度79.5%、特异度70.5%。与HACOR评分联合时,该NLR界值特异度提高而敏感度降低。
要点
- 急诊COPD急性加重无创通气患者中,NLR预测无创通气失败的AUC为0.804(95%CI 0.734-0.875),优于CRP的0.680和降钙素原的0.682。
- NLR预测无创通气失败的最佳界值为5.8,敏感度79.5%、特异度70.5%。
- 151例中73例(48.3%)无创通气失败,失败者相关死亡率为30.1%。
- NLR界值与HACOR评分联合时特异度提高、敏感度降低。
- 该研究为前瞻性队列,在三级中心急诊科进行,连续纳入符合无创通气指征的COPD急性加重患者。
适用人群与场景
- 三级中心急诊科连续就诊、COPD急性加重且符合无创机械通气指征的患者。
诊断标准与关键阈值
- NLR预测无创通气失败的最佳界值为5.8,敏感度79.5%、特异度70.5%。
研究设计与关键结果
- 前瞻性队列研究,纳入151例急诊COPD急性加重接受无创通气的患者,73例(48.3%)发生无创通气失败,失败相关死亡率为30.1%。
- NLR预测无创通气失败的AUC为0.804(95%CI 0.734-0.875),CRP为0.680(95%CI 0.594-0.765),降钙素原为0.682(95%CI 0.596-0.767)。
- NLR最佳界值5.8预测无创通气失败的敏感度79.5%、特异度70.5%。
- NLR界值与HACOR评分联合时特异度提高、敏感度降低。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为NLR是急诊COPD急性加重患者无创通气失败的最强预测指标,优于CRP和降钙素原。
- 作者认为生物标志物与HACOR评分联合可显著提高预后准确性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Non-invasive mechanical ventilation (NIMV) represents a cornerstone therapy for acute chronic obstructive pulmonary disease (COPD) exacerbation in emergency department (ED) settings.
OBJECTIVES: Clinical predictors of NIMV response remain poorly characterized. This study sought to evaluate and compare the predictive capacity of different biomarkers for identifying patients at risk of NIMV failure during acute exacerbations.
METHODS: This prospective cohort study was conducted in the ED of a tertiary center from March 2023 to December 2024. Consecutive patients presenting with acute COPD exacerbations and meeting criteria for NIMV were enrolled. The primary outcome (NIMV failure) was evaluated during the initial 2-h monitoring period. The predictive performance of C-reactive protein (CRP) and procalcitonin levels, and neutrophil-to-lymphocyte ratio (NLR) were assessed using receiver operating characteristic (ROC) curve analysis. Areas under the curve (AUC) were compared using the de-Long method.
RESULTS: Among 151 enrolled patients, 73 (48.3 %) experienced NIMV failure, with an associated mortality rate of 30.1 %. For NIMV failure, ROC analysis demonstrated superior predictive performance for NLR (AUC = 0.804, 95 % confidence interval [CI]:0.734-0.875) compared to CRP (AUC = 0.680, 95 % CI:0.594-0.765) and procalcitonin (AUC = 0.682, 95 % CI:0.596-0.767). ROC analysis identified an optimal NLR cutoff of 5.8 for predicting NIMV failure, demonstrating 79.5 % sensitivity and 70.5 % specificity. When integrated with the HACOR score, this NLR threshold showed enhanced specificity with reduced sensitivity.
CONCLUSION: The present study demonstrated that NLR was the strongest predictor of NIMV failure in the ED compared to CRP or procalcitonin. The combination of biomarkers with the HACOR score significantly enhanced prognostic accuracy.
参考来源
- Çatal HS, Doğan NÖ, Özturan İU, et al. Comparison of procalcitonin, C-reactive protein and neutrophil/lymphocyte ratio in prediction of noninvasive mechanical ventilation failure in patients admitted to the emergency department with COPD exacerbation. Am J Emerg Med. 2025. PMID: 41237671. doi:10.1016/j.ajem.2025.11.009
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。